Regular readers of Kamich's Korner on Real Money know that I periodically find interesting stocks to purchase or avoid by culling names generated by TheStreet's Quant Ratings. Jazz Pharmaceuticals Inc. (JAZZ) was recently upgraded to a buy recommendation by our quant service.
Let's check out the charts and indicators of this leader in sleep medicine and with a growing hematology/oncology portfolio.
In the daily bar chart of JAZZ, below, we can see that the shares sold off sharply from January into late March before a rebound got under way. Prices have recovered enough to test the bottoming 200-day moving average line. JAZZ is above the rising 50-day moving average line.
In this weekly Point and Figure chart of JAZZ, below, we can see a possible longer-term price target of $173 being projected.